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vancomycin US$3909.2, daptomycin US$6131.2 and tigecycline US$5509.0. The 
treatment with linezolid was associated with a shorter stay in the intensive care 
unit (7 days on average) which reduces the cost of treatment because it allowed 
the switch from intravenous to oral administration (5 days on average). Results 
for each alternative in QALYs were: linezolid 0.063, vancomycin 0.060, 
daptomycin 0.061 and tigecycline 0.059. The results for each alternative in terms 
of percentage of patients cured were: linezolid 84.4%, vancomycin 74.7%, 
daptomycin 78.1% and tigecycline 70.4%. The model results indicate that 
linezolid is dominant compared to vancomycin, daptomycin and tigecycline. 
Probabilistic sensitivity analyses showed the robustness of these findings. 
CONCLUSIONS: Linezolid is a cost-saving alternative in the treatment of cSSTI in 
the Chilean National Fund of Health (FONASA).  
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OBJECTIVES: The objective of this research is to evaluate the cost-effectiveness 
of linezolid 600mgBID(LI), vancomycin 1gBID(VA) and teicoplanin 400mgBID(TE) 
in the treatment of nosocomial pneumonia caused by MRSA under the private 
health care system perspective. METHODS: To compare the options, a decision 
tree model was built considering an arm per treatment option, from which 
patients could respond to the initial treatment and continue to maintenance 
treatment using the same antibiotics, or do not respond, and repeat the 
treatment with assumed 50% chance to use one of the other two antibiotics. 
Clinical or microbiological effectiveness could be used as determinants of 
response. Effectiveness measures were mortality, clinical and microbiological 
responses, calculated by an indirect comparison of a literature systematic 
review. Hospitalization days were evaluated. Only direct costs were considered, 
and were obtained from CBHPM2010 for medical procedures, CMED 
December2012, considering X-factory price plus 18% tax for medications  
and BRASINDICE December2012 for materials. Values were represented in 
2012USD. A time horizon of 1 year was considered. RESULTS: Clinical response 
rates were 66.5%(VA), 68.3%(TE), 72.6%(LI), microbiological response rates were 
56.1%(VA), 55.9%(TE), 64.4%(LI), mortality rates were 15.74%(VA), 13.56%(TE), 
10.13%(LI). If clinical response was considered as a determinant of success, the 
treatment costs would be US$33,190.76(VA), US$41,657.71(TE), US$27,036.62(LI), 
hospitalization days would be 41(VA), 39(TE), 26(LI), and if microbiological 
response was considered, the treatment costs would be US$34,597.12(VA); 
US$42,574.61(TE), US$28,514.48(LI) and hospitalization days would be 42(VA), 
40(TE), 28(LI). Incremental cost-effectiveness ratios for TE and LI when compared 
to VA for clinical response were US$470,386.13, -US$100,887.50(dominant),  
and for microbiological response were -US$398,874.67(dominated),  
-US$73,284.78(dominant) respectively. CONCLUSIONS: Compared to 
vancomycin, teicoplanin was either dominated or did not reach cost-
effectiveness considering a willingness to pay of US$32,621.93 (3xBrazilian GDP 
per capita), whereas linezolid was dominant, presenting lower mortality while 
offsetting costs, mainly driven by less hospitalization days at private health care 
services.  
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OBJECTIVES: Aspergillosis is the second cause of invasive fungal infections with 
high mortality rates. The objective of this research is to evaluate the cost-
effectiveness of amphotericin B(AB) 1.5mg/kg/day, amphotericin B liposomal(AL) 
3mg/kg/day, caspofungin(CA) 50mg/day, voriconazol 8mg/kg/day(VO) including 
maintenance oral Voriconazol 400mg/day scheme in the treatment of 
aspergillosis under the Brazilian public health care system perspective. 
METHODS: To compare the options, a decision tree model was built considering 
sequential treatments, from which patients could respond to one initial 
treatment and continue to a maintenance phase of the same medication, or do 
not respond due to either inefficacy or adverse events and switch treatments 
with assumed equal chance to use one of the other options. Effectiveness 
measures were mortality, clinical response and days of hospitalization, 
calculated by indirect comparison of a literature systematic review. Only direct 
costs were considered, and were obtained from the publicly available databases 
of DATASUS. Values were represented in 2012USD. A time horizon no longer 
than 4 weeks was considered, thus discounting was not applied. One-way 
sensitivity analysis considered de-hospitalization in maintenance phases while 
using oral Voriconazol. RESULTS: Clinical response rates were 36.40%(AB), 
34.60%(AL), 34.20%(CA), 56.67%(VO), mortality rates were 50.90%(AB), 48.70%(AL), 
44.70%(CA), 34.10%(VO) and hospitalization days were 26.35(AB), 24.68(AL), 
25.33(CA), 22.55(VO). Expected treatment costs were 18,380.91USD(AB), 
53,076.12USD(AL), 27,145.04USD(CA) and 24,510.88USD(VO). Considering AB as 
the baseline for cost-effectiveness, VO presented an incremental cost-
effectiveness ratio(ICER) of 30,241.60 while other options were dominated with 
higher costs and lower effectiveness. If de-hospitalization was considered, VO 
arm would sum 14.62 hospitalization days, treatment cost of 23,299.90USD and 
an ICER of 24,267.34USD. CONCLUSIONS: Assuming a willingness to pay of 
32,621.93USD (3 times Brazilian 2011GDP per capita), VO was the only cost-
effective option compared to AB, additionally presenting lower mortality and less 
hospitalization days while allowing early de-hospitalization at public health care 
services.  
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OBJECTIVES: Strategies for monitoring antiretroviral therapy (ART) include 
clinical assessment, CD4 testing, and viral load (VL) testing. Although benefits of 
VL monitoring have been established, it is considered too expensive to 
implement in low-income settings. Several studies have found varying levels of 
cost-effectiveness (CE) of VL monitoring. We reviewed the studies and evaluated 
their quality to identify gaps in evidence of potential CE of VL testing in low-
income settings. METHODS: We performed a systematic review of studies with a 
cost analysis using a Medline search from 1980-2012 with keywords ‘cost’, 
‘economic’, ‘viral load’, and ‘HIV’. We assessed study quality using the validated 
Quality of Health Economic Scales (QHES) questionnaire and the Drummond 
criteria. RESULTS: We identified and included eight studies. QHES scores ranged 
from 44 to 83 (on a scale of 0-100). Two methodologically strong studies used 
Markov models, and three used high quality cohort data. One study was 
performed among children, one used clinical trial data that may not be 
generalizable, and one did not include a CD4 monitoring strategy. Incremental 
CE ratios ranged from $86/life-year to $68,698/quality-adjusted life-year and were 
most sensitive to cost of VL test kits, followed by treatment failure rates and 
utilities. Two studies found VL testing to be CE (<3 times gross domestic product 
(GDP)/capita), and three found it to be highly CE (<1 times GDP/capita). Only one 
study included a societal perspective, which found VL monitoring to be cost 
saving. CONCLUSIONS: This evidence suggests that VL testing may be CE in low-
income settings. The five studies that were methodologically strong and utilized 
high quality data found VL monitoring CE or highly CE. Reduced costs of VL test 
kits may further enhance CE. Future studies are needed to address 
methodological and data quality issues as well as use of a societal perspective.  
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OBJECTIVES: Community acquired pneumonia (CAP) still represents an 
important disease in Mexico. The study of both economic and clinical outcomes 
of treatments remains relevant. The aim of this study was to assess the 
consequences of the use of antibiotics to treat CAP, from the perspective of 
Instituto Mexicano del Seguro Social (IMSS). METHODS: A decision tree model 
that considers clinical success and failure either whit first and second line 
treatments, presentation or not of adverse events (AE´s), as well as death was 
developed. The antibiotics considered in the assessment were: clarithromycin 
(1,000 mg/day), levofloxacin (1,000 mg/day), ceftriaxone (1,000 mg/day), 
cefuroxime (1,500 mg/day), moxifloxacin (400 mg/day) and gemifloxacin (320 
mg/day). The last option is not listed in IMSS formulary. Clinical data were 
extracted from international literature. Effectiveness measures were clinical 
success rate and length of stay (LOS). The model considered direct medical costs 
(2012 US$): drugs, diagnostic tests, physician visits, LOS, emergency room and 
intensive care unit; cost were extracted from institutional sources. Resource use 
for CAP was extracted from clinical files (n=94 adult patients) treated at one IMSS 
hospital, whereas resource use for AE´s treatment was obtained through expert 
opinion (panel). One-way sensitivity analysis and acceptability curves were 
performed. RESULTS: The alternative that presented the most favorable 
pharmacoeconomic profile was gemifloxacin ($3237 per patient, 95.3% of success 
rate and 6.22 days of LOS), followed by levofloxacin and clarithromycin, with 
marginal differences in clinical success but around $1600 of incremental cost. 
The alternative with the less favorable profile was moxifloxacin: $1784.52 of 
incremental cost, -8.8% of clinical success and +6.6 days of LOS regarding 
gemifloxacin. The results were robust to +10% acquisition cost and +5% AE´s 
incidence for gemifloxacin. CONCLUSIONS: Alternatives with potential to 
promote savings in the management of CAP (like gemifloxacin) are valuable, 
which becomes more relevant in contexts with limited resources.  
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OBJECTIVES: Benefits of QIV over trivalent inactivated vaccine (TIV) are 
dependent on the proportion of influenza circulation attributable to influenza-B 
and the extent of vaccine matching with respect to circulating B-lineages. 
Applying the 2000-2010 influenza data from the Health Protection Agency, the 
impact of vaccination with QIV versus TIV on influenza morbidity and mortality 
in the UK was evaluated to estimate potential benefits of QIV if it had been 
available during this time. METHODS: Using current influenza management 
guidance (vaccination of those at-risk and the elderly), a multi-cohort, static, 1-
year decision model was used. Influenza A and B was accounted for separately. 
Vaccine efficacy data was derived from Cochrane Databases (TIV) and meta-
analyses (QIV). The model considers the perspective of the UK National Health 
Service. RESULTS: Using the average influenza-B circulation and vaccine 
